Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services

Aragen appoints Neeraj Garg as CEO - Discovery Solutions business

In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base

Syngene International invests in peptide laboratory in Bengaluru

Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services

Sai Life Sciences opens dedicated facility for veterinary APIs in Bidar

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore